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ABSTRACT
In addition to the 7 transmembrane receptor (7TM)-conserved
disulfide bridge between transmembrane (TM) helix 3 and
extracellular loop (ECL)-2, chemokine receptors (CCR) contain
a disulfide bridge between the N terminus and what previously
was believed to be ECL-3. Recent crystal and NMR structures of
the CXC chemokine receptors (CXCR) CXCR4 and CXCR1,
combined with structural analysis of all endogenous chemokine
receptors indicate that this chemokine receptor–conserved
bridge in fact connects the N terminus to the top of TM-7. By
employing chemokine ligands that mainly target extracellular
receptor regions and small-molecule ligands that predominantly
interact with residues in the main binding crevice, we show that
the 7TM-conserved bridge is essential for all types of ligand-
mediated activation, whereas the chemokine-conserved bridge
is dispensable for small-molecule activation in CCR1. However,
in striking contrast to previous studies in other chemokine
receptors, high-affinity CCL3 chemokine binding was main-
tained in the absence of either bridge. In the highly related
CCR5, a completely different dependency was observed as
neither activation nor binding of the same chemokines was
retained in the absence of either bridge. In contrast, both bridges
were dispensable for activation by the same small molecules.
This indicates that CCR5 activity is independent of extracellular
regions, whereas in CCR1 the preserved folding of ECL-2 is
necessary for activation. These results indicate that conserved
structural features in a receptor subgroup do not necessarily
provide specific traits for the whole subgroup but rather provide
unique traits to the single receptors.
Introduction
Chemokine receptors belong to class A 7 transmembrane
receptors (7TM), which have a highly conserved disulfide
bridge between the extracellular end of transmembrane helix
(TM) 3 and extracellular loop (ECL)-2. Recent crystal struc-
tures show that this 7TM-conserved bridge forces ECL-2 to
form a lid over the binding pocket, and that ECL-2 contains
well-defined but rather different secondary structures within
the different receptor families (Palczewski et al., 2000;
Rasmussen et al., 2007; Jaakola et al., 2008; Scheerer et al.,
2008; Warne et al., 2008; Wu et al., 2010; Park et al., 2012).
Furthermore, among class A receptors, ECL-2 is on average
the longest of the three ECLs and is believed to be critical for
proper ligand binding and receptor activation (Peeters et al.,
2011).
The presence of additional extracellular disulfide bridges in
certain 7TM receptor families are believed to provide further
structural constraint of importance for the regulation of
receptor function and ligand binding (Peeters et al., 2011).
Such an additional disulfide bridge is present and highly
conserved among chemokine receptors, as shown in the
structures of the CXC chemokine receptors (CXCR) CXCR1
and CXCR4 (Wu et al., 2010; Park et al., 2012). The
chemokine system is essential for the immune system as
mediator of cell migration during homeostasis and inflam-
mation, and activation and differentiation of lymphoid cells
and functions outside the hematopoietic system (e.g., angio-
genesis and cell growth). This large receptor family consists of
10 CC chemokine receptors (CCR1–10), seven CXC chemo-
kines (CXCR1–7), two XC-chemokines 1 and 2, and one CX3C-
chemokine receptor, named according to their preferred
endogenous ligands. However, the interaction between che-
mokines and their receptors varies from high selectivity to
high promiscuity, where the same chemokine binds several
receptors and several chemokines bind to the same receptor
(Rossi and Zlotnik, 2000). This redundancy poses a huge
challenge in drug development. Nevertheless, due to the
central role of the chemokine system in immune control, many
small-molecule ligands have been developed. These often
share a similar pharmacophore with a positively charged
group that anchors to the chemokine receptor–conserved
glutamic acid in TM-7 (position VII:06/7.39) (Rosenkilde and
dx.doi.org/10.1124/mol.113.086702.
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Schwartz, 2006). [The nomenclature for the positions of
transmembrane-located residues within the 7TM receptors
are provided according to the nomenclature suggested by
Baldwin (1993) and Schwartz (1994), followed by the one
suggested by Ballesteros and Weinstein (1995).] However, de-
spite strong research efforts, only two small-molecule ligands,
maraviroc (CCR5) and mozobil (CXCR4), have reached the
market (Brave et al., 2010; Maeda et al., 2012).
The chemokine receptor–conserved disulfide bridge is located
between Cys residues in the N terminus and in what was
previously believed to be ECL-3. However, in the structures of
CXCR1 and CXCR4, the Cys residue partnering with the
N-terminal Cys is located in the top of TM-7, not in ECL-3. This
conserved bridge can be formed in all endogenous receptors
except for CXCR6, which lacks the N-terminal Cys. The impact
of these two disulfide bridges has been studied in a handful of
chemokine receptors, where disruption of either bridge was
found to reduce receptor surface expression (CXCR4 and CCR5)
(Blanpain et al., 1999; Chabot et al., 1999) and/or abolish
chemokine binding (CXCR2, CCR5, and CCR6) (Blanpain et al.,
1999; Ai andLiao, 2002; Limatola et al., 2005). This large impact
on chemokine interaction is not surprising, as chemokines, due
to their large size, primarily interact with the extracellular parts
of the receptor (Schwarz and Wells, 2002; Allen et al., 2007),
making them critically dependent on correct folding of these
regions.
In the present study, we focus on the impact of the disulfide
bridges for receptor activity and ligand binding in two closely
related CC-chemokine receptors: CCR1 and CCR5. Initial
bioinformatic analyses of all endogenous chemokine receptors
revealed that despite a large diversity in the extracellular
domains, the positions of the four Cys residues are extremely
conserved (Fig. 1). CCR1 was chosen due to the availability of
both peptide and nonpeptide agonists and antagonists. Thus,
the two chemokine agonists CCL3 and CCL5 were included
together with the CCR1-selective nonpeptide antagonist
BX471 (Horuk, 2005) as well as two chemically different
series of small-molecule agonists: a novel carbamide-based
series (Jensen et al., 2012; Petersen et al., 2013) andmetal-ion
chelators (Jensen et al., 2008; Thiele et al., 2012). As CCR5 is
the closest homolog to CCR1 and overlaps in ligand-binding
profiles with CCR1 (Murphy et al., 2000; Jensen et al., 2008;
Thiele et al., 2011, 2012), similar studies were performed on
CCR5.
Despite structural and functional homology between the
receptors, our experiments revealed opposite impacts of the
disulfide bridges on ligand binding and receptor function. This
indicates that even though a structural feature (such as the
disulfide bridges in chemokine receptors) is extremely con-
served among a large subgroup of receptors, it does not
necessarily provide a specific functional trait for the given
subgroup but rather unique traits to single receptors within
the subgroup.
Materials and Methods
CCL3 was purchased from R&D Systems (Minneapolis, MN). The
cDNA for wild-type (WT) human CCR1 was kindly provided by Tim
Wells (Serono Pharmaceutical Research Institute, Geneva, Switzer-
land), and the WT CCR5 was cloned in house from a spleen cDNA
library. 3H-myo-inositol (PT6-271) and 125I-CCL3 were purchased from
Amersham Pharmacia Biotech (Uppsala, Sweden). The promiscuous
chimeric G protein GaD6qi4myr, was kindly provided by Evi Kostenis
(University of Bonn, Germany).
Site-Directed Mutagenesis. Point mutations were introduced in
the receptor by use of the polymerase chain reaction overlap extension
technique with human chemokine receptors as a template. All
reactions were performed with Pfu polymerase (Stratagene, La Jolla,
CA). The mutant receptors were cloned into the eukaryotic expression
vector pcDNA3.11 and were expressed in Escherichia coli cells. The
mutations were verified by DNA sequencing by Eurofins MWGOperon
(Ebersberg, Germany).
Transfections and Tissue Culture. COS-7 cells were grown in
10% CO2 at 37°C in Dulbecco’s modified Eagle’s medium with
glutamax (cat. no. 21885-025; Invitrogen/GIBCO, Long Island, NY)
adjusted with 10% fetal bovine serum, 180m/ml penicillin, and 45 mg/ml
streptomycin. Transfection of COS-7 cells was performed by the
calcium phosphate precipitation method. In 75 cm2 flasks, 10 mg
receptor DNA and 15 mg GaD6qi4myr were mixed with 30 ml 2 mM
CaCl2 and Tris-EDTA buffer for a total volume of 240 ml. We added
240 ml 2x Hanks’ buffered salt solution, and the mixture was given 45
minutes for precipitation before it was added to the cells along with
2 mg/ml of cloroquine. The flasks were incubated for 5 hours at 37°C
before the media were replaced with 10 ml fresh COS-7 media.
Inositol-Phosphate Assay (IP Turnover). COS-7 cells were trans-
fected as described previously. The cotransfection with GaD6qi4myr
turns the Gi signal into a Gq coupled signal, making it possible to
measure the phospholipase C (PLC) activation as inositol-phosphate
(IP) turnover. One day after transfection, the cells were seeded in 24-
well plates (1.5  105 cells/well) and incubated with 2 mCi of 3H-myo-
inositol in 0.3 ml growth medium for 24 hours. Cells were washed
twice with Hanks’ balanced salt solution supplemented with CaCl2
and MgCl2 (GIBCO14025) and afterward were incubated for 15
minutes in 0.2 ml of buffer supplemented with 10 mMLiCl before the
ligand addition followed by 90 minutes of incubation. Cells were
extracted by addition of 1ml of 10mM formic acid followed by incubation
on ice for 30 minutes. The generated [3H]inositol phosphate was pu-
rified on AG 1X8 anion exchange resin. Determinations were made in
duplicate.
Binding Experiments. COS-7 cells were transiently transfected,
then transferred to culture plates and left overnight. The number of
cells seeded per well was determined by the apparent expression
efficiency of the receptor and was aimed to obtain 5 to 10% specific
binding of the added radioactive ligand. The competition binding was
carried out for 3 hours’ incubation at 4°C using 10–15 pM 125I-CCL3
along with the unlabeled ligand in 0.3ml 50mMHEPES buffer pH 7.4
supplemented with 1mMCaCl2, 5 mMMgCl2, and 0.5% bovine serum
albumin (BSA). After incubation, the cells were washed twice in 4°C
binding buffer supplemented with 0.5 M NaCl. Nonspecific binding
was determined as the binding in the presence of 0.1 mMunlabeled CCL1,
CCL3, or CCL5, respectively. Determinations were made in duplicate.
Bmax values were calculated based on the homologous competition binding
experiments by the following formula: [(Top of curve in counts per minute
[CPM] 2 Bottom of curve in CPM) * IC50 (M) * Assay Volume (L) * 10
15]/
[Total radioactivity (in CPM) * 105 cells] 5 fmol/105 cells.
Surface Enzyme-Linked Immunosorbent Assay. COS-7 cells
were transiently transfected with N-terminal M1-FLAG tagged
receptor mutant receptors, and seeded in 96-well plates (35,000
cells/well). The cells were washed once in Tris-buffered saline (TBS)
(50 mM Tris-base, 150 mM NaCl, pH 7.6), and subsequently fixed in
150 ml 4% formaldehyde for 15 minutes. After three washes in TBS,
the cells were blocked in TBS containing 2% BSA for 30 minutes.
Subsequently, the cells were incubated with mouse M1 anti-FLAG
antibody 2 mg/ml in TBS containing 1% BSA and 1 mM CaCl2 for 2
hours. After three washes in TBS with 1 mM CaCl, the cells were
incubated with goat anti-mouse horseradish peroxidase-conjugated
IgG antibody diluted 1:1000 in TBS containing 2% BSA and 1 mM
CaCl2 for 1 hour. After three washes in TBS 1 mM CaCl2 the immune
reactivity was revealed by addition of horseradish peroxidase substrate
according to the manufacturer’s instructions.
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b-Arrestin Recruitment. Recruitment of b-arrestin was mea-
sured using the PathHunter b-arrestin assay (DiscoverX, Fremont,
CA). The CCR1 and CCR5 wild-type receptors were fused with the
ProLink pk1-tag (a small fragment of the enzyme b-galactosidase)
and cloned into a pCMV-vector. Mutations were made with
QuikChange polymerase chain reaction (Agilent Technologies, Santa
Fig. 1. Positional conservation of the cysteines in the extracellular disulfide bridges. Serpentine models of a chemokine receptor emphasizing the
position of the partnering cysteines relative to the conserved transmembrane residues in the class A 7TM-conserved disulfide bridge (A) and in the
chemokine receptor-conserved disulfide bridge (D). A graphical presentation of the number of amino acids from a conserved extracellular cysteine to
a conserved transmembrane residue for the class A 7TM-conserved disulfide bridge (B and C) and for the chemokine receptor-conserved disulfide bridge
(E and F). CXCR6 is highlighted in red to emphasize lack of the chemokine-conserved disulfide bridge.
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Clara, CA). Assays were performed in a Chinese hamster ovary K1
enzyme acceptor-arrestin cell line stably expressing b-arrestin1 or
b-arrestin2 coupled to the large b-galactosidase fragment. Cells were
seeded out in 96-well plates, 20,000 cells/well, and transfected the
following day with 50 ng DNA using FuGENE6 (Promega, Madison,
WI) reagent (0.15 ml/well). Then, 24 hours after transfection, the
medium was removed, and 100 ml Opti-MEM I (GIBCO) was added.
The next day, the cells were stimulated with varying concentrations of
CCL3 or CCL5 for 90 minutes at 37°C. The detection reagent solution
was added before the 60-minute incubation at room temperature,
and the b-arrestin recruitment was measured as chemiluminescence
using the PerkinElmer EnVision 2104 Multilabel Reader (PerkinElmer,
Waltham, MA).
Bioinformatics. The nucleotide sequences of the chemokine
receptors were acquired from GenBank of National Center for
Biotechnology Information (www.ncbi.nlm.nih.gov). The alignment
was performed in Geneious 6.0.5 (Biomatters Ltd., Auckland, New
Zealand) using MAFFT v6.814b (http://mafft.cbrc.jp/alignment/
software/). The BLOSUM62 matrix was applied with gap open
penalty and offset value of 1.53 and 0.123, respectively. The sequence
logo was generated using the Internet-based programWebLogo (http://
weblogo.berkeley.edu).
Results
Highly Conserved Localization of the Disulfide
Bridges and Length of Extracellular Regions in Che-
mokine Receptors. When we compare the positions of the
four extracellular cysteines involved in disulfide bridge
formation in chemokine receptors, it becomes evident that
there is a high degree of positional conservation (Fig. 1). The
relative position of the highly conserved cysteine at the top of
TM-3 (position III:01/3.25) is very constant (Fig. 1B, black
symbols) as expected from its presence in all class A 7TM
receptors (Mirzadegan et al., 2003). However, also the length
of ECL-1 is surprisingly conserved, with the majority of
receptors containing 25 amino acids between CysIII:01 and
the conserved Asp in TM-2 (II:10/2.50) (Fig. 1B, white
symbols). The localization of the partnering Cys in ECL-2
of the 7TM-conserved disulfide bridge is less conserved, as
reflected by a larger variability in the length of ECL-2,
although the length of ECL-2a (the part prior to the Cys) is
a bit more preserved than ECL-2b (the part from the Cys to
TM-5) (Fig. 1C). When examining the positions of the
cysteine residues in the chemokine receptor-conserved
disulfide bridge, there is a huge diversity in the length of the
region preceding the N-terminal Cys, reflecting that the main
chemokine binding motifs are localized in this region (Allen
et al., 2007) (Fig. 1E). However, at the same time there is
a striking degree of positional conservation in the N-terminal
Cys when considering the distance to the conserved AsnI:18/
1.50, as 16 out of 20 receptors have 28 amino acids in this
region, whereas the rest have 27 or 31 amino acids. The
relative position of the partnering Cys in TM-7 is also highly
conserved. Thus, in all chemokine receptors there are exactly
25 amino acids to the ProVII:17/7.50 (Fig. 1F, black
symbols); when counted from ProVI:15/6.50, there are either
19 or 20 (Fig. 1F, white symbols). Taken together, this highly
preserved positioning of not only the 7TM-conserved
disulfide bridge but also the chemokine receptor-conserved
disulfide bridge gives testament to the importance of struc-
tural conservation for the overall function of chemokine
receptors.
Reposition of One of the Cysteines in the Chemokine-
Conserved Disulfide Bridge from ECL-3 to the Top
of TM-7. The high positional conservation of the four ex-
tracellular cysteines specifies that the overall number of
residues and thus the lengths of the extracellular loops (and of
the region between the N-terminal Cys and TM-1) are very
similar within the chemokine family. When assessing the
published structures of CXCR1 and CXCR4, the same
tendencies are observed (Wu et al., 2010; Park et al., 2012).
We therefore looked at the primary structures in these re-
gions of all endogenous chemokine receptors. As shown in
Supplemental Fig. 1, there is generally low amino acid con-
servation in the extracellular receptor parts compared with
the transmembrane regions, reflecting that chemokine-
recognition relies on extracellular receptor regions (Allen
et al., 2007). However, there is a high degree of similarity in
certain smaller extracellular areas, such as the WxFG motif
in ECL-1 and the aromatic residue 4 amino acids after the Cys
in ECL-2 in 13 out of the 20 receptors. Importantly, the Cys, in
what was previously believed to be ECL-3, aligns to the top of
TM-7, as confirmed by the structures of CXCR1 and CXCR4
(Wu et al., 2010; Park et al., 2012). This indicates that the
chemokine receptor-conserved disulfide bridge links the N
terminus to the top of TM-7 and thereby confers less flexibility
to this bridge.
Both Bridges Are Essential for Chemokine-Mediated
Activation, but Not for Binding. To clarify the importance
of the overall structure of the extracellular regions for ligand
binding and receptor activation in CCR1, we constructed
single Ala substitutions of the four extracellular Cys residues,
thereby disrupting the 7TM-conserved bridge (between C106
in TM-3 and C183 in ECL-2) and the chemokine-conserved
bridge (between the N-terminal C24 and C273 in TM-7). The
mutated receptors were tested for their ability to be activated
by CCL3 and CCL5. Thus, COS-7 cells were transiently
transfected with plasmids containing any of the four Ala-
substituted receptors along with a chimeric G protein
(Gqi4myr) that is recognized as a Gai-subunit but transduces
a Gaq signal. Consequently, G protein–mediated activation
wasmeasured by IP3 accumulation. As seen in Fig. 2, A and B,
and Table 1, CCL3- and CCL5-mediated activation was highly
impaired and for some mutations completely absent, but they
acted as previously described on CCR1WT (Neote et al., 1993;
Jensen et al., 2008). Enzyme-linked immunosorbent assay-
based determination of surface expression uncovered WT-like
expression of [C24A]- and [C273A]-CCR1, but that of [C106A]-
and [C183A]-CCR1 (with disrupted 7TM-conserved bridge)
was reduced up to 6-fold compared with CCR1 WT (Table 1).
Given the preserved receptor expression, the impaired
activation (Fig. 2, A and B) could be due to either impaired
ligand binding or the mutations interfering with the overall
ability of the receptors to be activated. The CCL3 binding was
therefore determined by homologous competition binding,
and intriguingly all mutated receptors retained WT-like high-
affinity CCL3 binding (Fig. 2, C andD; Table 1), althoughwith
reduced maximum binding (Bmax) (Table 1). This high-affinity
CCL3 binding without triggering a G protein–mediated
activation prompted us to explore whether non-G protein–
dependent pathways were affected as well. This was indeed
the case, as the b-arrestin recruitment was completely
abolished in all four mutations, whereas CCL3 induced
high-potency b-arrestin recruitment in CCR1 WT (Fig. 3).
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Disruption of the 7TM-Conserved Bridge Also
Impairs Activation by Small-Molecule Agonists, but
These Act Independently of the Chemokine-Conserved
Bridge. Given their small size and thus more restricted
binding mode compared with the endogenous ligands (Handel
and Lau, 2004; Jensen et al., 2008), two series of small-
molecule agonists (metal-ion chelators and carbamide-based
agonists) served as valuable tools for investigating whether
the impaired activation by CCL3 was due to a general
impaired receptor activation or to an altered CCL3 targeting
to CCR1. Upon disruption of the 7TM-conserved bridge, the
activation of the metal-ion chelator complexes (Cu in complex
with bipyridine and phenanthroline) were severely impaired,
but these ligands acted with WT-like potencies and efficacies
in the absence of the chemokine-conserved bridge (Fig. 4, A
and B; Table 2). The same pattern was observed for the more
potent carbamide-based CCR1 agonist 4-(3-phenoxy-benzyl)-
homopiperazine-1-benzyl-carboxamid (TUG-584) (Supple-
mental Fig. 2, A and B), thus demonstrating that the
chemokine-conserved bridge—in contrast to the 7TM-conserved
bridge—is not essential for activation as such, only for
activation mediated by the chemokines.
Positive Allosteric Modulators Shift toward Compet-
itive Antagonism in the Absence of the 7TM-Conserved
Bridge. Due to themaintained ligand-binding but differential
impact of the two disulfide bridges on ligand-mediated
Fig. 2. Disruption of conserved disulfide bridges impairs chemokine
action but maintains binding. IP-accumulation experiments in transiently
transfected COS-7 cells are given in CPM values (A and B) and binding
experiment curves, normalized against own CCL3 binding (C and D), of
CCR1 WT (u), [C24A]-CCR1 (.), [C106A]-CCR1 (m), [C183A]-CCR1 (j),
and [C272A]-CCR1 (d) (n = 3–78).
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activation, we explored whether the positive allosteric proper-
ties, previously reported for the metal-ion chelators in CCR1
WT (Jensen et al., 2008; Thiele et al., 2012), were affected.
Consistent with the preserved activity of these small-molecule
agonists (Fig. 4B), the positive allosteric enhancement was
maintained with WT-like affinities in the absence of the
chemokine-conserved bridge (Fig. 4D), In contrast, the metal-
ion chelator complexes lost their ability to enhance 125I-CCL3
binding upon disruption of the 7TM-conserved disulfide bridge;
in fact, they displayed an entirely different binding pattern, as
Fig. 3. b-arrestin recruitment depends on maintained disulfide bridges.
CCL3 induced b-arrestin recruitment of (A) CCR1WT (u), [C106A]-CCR1
(m), and [C183A]-CCR1 (j) and (B) CCR1 WT (u), [C24A]-CCR1 (.), and
[C273A]-CCR1 (d). All curves are normalized against CCL-3 induced
b-arrestin recruitment at CCR1 WT (n = 3).
Fig. 4. Small molecule activation in CCR1 is impaired and shift toward
competitive antagonism when the 7TM-conserved bridge is disrupted. (A
and B) IP-accumulation experiments of Cu2+ phenanthroline (CuPhe) on
CCR1 WT (u), [C24A]-CCR1 (.), [C106A]-CCR1 (m), [C183A]-CCR1 (j)
and [C273A]-CCR1 (d). All results have been normalized to CCR1WT (n =
3-14). C and D, [C183A]-CCR1 represents disruption of the 7TM-
conserved bridge (C) and [C273A]-CCR1 represents disruption of the
chemokine-conserved bridge (D). Heterologous binding of CuPhe on
CCR1 WT (u), and mutant receptors (j). All curves are normalized to
CCR1 WT (n = 3–7).
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they shifted toward being competitive ligands for 125I-CCL3
binding (Fig. 4C). Consequently, these binding data support
the dependency of the 7TM-conserved disulfide bridge for the
agonistic properties of these small molecules (Fig. 4, A and B).
Besides showing that the metal-ion chelators in fact bind to the
receptors with high affinity, these results intriguingly show
how disruption of the 7TM-conserved bridge alters the ligand-
binding mode.
Endogenous Ligand Binding Is Altered upon Disrup-
tion of the 7TM-Conserved Bridge, Whereas Small-
Molecule Interaction Is Retained. To further explore the
altered ligand-binding mode, we constructed CCR1 receptors
lacking the conserved GluVII:06/7.39 in the absence of the
7TM-conserved bridge [C106A-E287A]-CCR1 and [C183A-
E287A]-CCR1. This Glu residue acts as an anchor point for
the metal-ion chelators, whereas the interaction of CCL3 with
CCR1 is independent of this residue (Jensen et al., 2008).
Despite the maintained surface expression, no specific
125I-CCL3 binding was observed in any of the two double-
mutant receptors (Table 1). This suggests that CCL3—in the
absence of the 7TM-conserved bridge—is dependent on E287
for proper CCR1 interaction, and that the altered competitive
nature observed for the small-molecule agonists (Fig. 4C)
could be centered on a mutual interaction with this specific
residue.
To ensure proper folding of the CCR1 mutant receptors, we
performed heterologous competition binding experiments
with the CCR1-specific small-molecule antagonist BX471.
This ligand has a well-established binding mode consisting
primarily of aromatic interactions in the main binding cre-
vice, where it spans the whole binding pocket interacting with
TM-1, TM-2, TM-3, and TM-7 (Vaidehi et al., 2006). As seen in
Supplemental Fig. 2, C and D, BX471 displaced 125I-CCL3
with WT-like affinities in all four Cys-substituted receptors,
indicating that the main binding crevice is maintained in the
absence of the disulfide bridges.
Different Roles of the Extracellular Areas in CCR5
and CCR1. Because CCR5 ligand-binding profile overlaps
with that of CCR1 (Murphy et al., 2000; Jensen et al., 2008;
Thiele et al., 2011, 2012), we decided to construct the cor-
responding Ala-substitutions: [C20A]-, [C101A]-, [C178A]-,
and [C269A]-CCR5. Similar to CCR1, chemokine-induced G
protein activation could not be obtained for any of these
mutations (Fig. 5, A and B; Table 3). This was not because of
a lack of receptor surface expression, as all four Cys-to-Ala
substitutions displayed.50% of WT expression (Table 3). Like
for CCR1, the chemokine-induced b-arrestin recruitment was
absent in the mutant receptors (unpublished data). However,
in contrast to CCR1, and despite maintained surface expres-
sion, no specific binding of 125I-CCL3was observed in any of the
CCR5 mutations (Fig. 5, C and D).
Maintained Small-Molecule Activity in the Absence
of Disulfide Bridges in CCR5. Another noticeable differ-
ence from CCR1 was observed when studying the small
molecules. Thus, in contrast to the highly impaired CCR1
lacking the 7TM-conserved bridge (Figs. 2 and 4), the similar
disruption in CCR5 was insignificant for small molecule
activation. Here, the metal-ion chelators as well as the
carbamide-based ligand TUG-588 acted with WT-like poten-
cies in both [C101A]- and [C178A]-CCR5 (Fig. 6A; Supple-
mental Fig. 2, E and F; Table 3); however, compared with the
metal-ion chelator efficacies on CCR5 WT, we observed a 50%
decrease (Table 3). The same independency was observed
upon disruption of the chemokine-conserved bridge in CCR5
(Fig. 6B; Table 3), as was the case in CCR1 (Fig. 4, C and D).
Thus, there was no difference between CCR1 and CCR5 with
regard to the impact of the chemokine-conserved bridge for
small-molecule agonist action, whereas in CCR5 the small-
molecule activation was maintained despite disruption of the
7TM-conserved bridge.
Discussion
We have assessed the importance of the conserved disulfide
bridges for CCR1 function and compared it with CCR5. The
strong positional conservation for the implicated cysteine
residues and thereby also the length conservation of the
involved extracellular regions are striking observations (Fig.
1). By employing chemokines that mainly target extracellular
regions and small-molecule agonists that target the main
binding crevice, we show that the disulfide bridges have
different impacts, despite the overlapping ligand-binding
profiles and structural similarities for CCR1 and CCR5
(summarized in Fig. 7).
The Disulfide Bridge between TM-3 and ECL-2 Is
a Conserved Structural Trait Among 7TM Receptors.
The presence of disulfide bridges in the extracellular parts of
7TM receptors are believed to be important for the receptor
Fig. 5. Endogenous ligand activation and binding is not retained in
CCR5, when disrupting either of the two disulfide bridges. IP-accumula-
tion experiments in transiently transfected COS-7 cells, given as CPM
values (A and B), and binding experiments curves, normalized against
CCL3 binding on CCR5WT (C and D), of CCR5WT (u), [C20A]-CCR1 (.),
[C101A]-CCR1 (m), [C178A]-CCR1 (j) and [C269A]-CCR1 (d) (n = 3–78).
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rigidity as well as to provide general important mechanisms
for receptor regulation (Peeters et al., 2011). The disulfide
bridge between TM-3 and ECL-2 is present in 92% of all class
A receptors (Storjohann et al., 2008), and early (precrystal)
structure studies showed an essential role of this bridge for
rhodopsin stability (Davidson et al., 1994). Similar experi-
ments in the gonadotropin- and thyrotropin-releasing hor-
mone receptors, m-opioid, bradykinin, muscarinic, vasopressin,
and NK1 receptors have shown reduced ligand activation
caused by impaired ligand binding upon disruption of this
bridge (Davidson et al., 1994; Perlman et al., 1995; Herzig
et al., 1996; Cook and Eidne, 1997; Zeng et al., 1999; Zhang
et al., 1999; Elling et al., 2000; Conner et al., 2007; Storjohann
et al., 2008). Experiments in chemokine receptors include
CXCR4, where the 7TM-conserved bridge was found to be
important for maintained receptor structure because a series
of structure-dependent antibodies was not able to recognize
CXCR4 with single or double Ala substitutions of the
corresponding Cys residues (Chabot et al., 1999). Moreover,
disruption of the disulfide bridge retained at least 90% of the
receptor population intracellularly (Chabot et al., 1999).
Similar findings were made in CCR5, where Ala substitution
of these Cys residues reduced surface expression by 40–70%
and structure-dependent antibodies and CCL4 failed to
recognize any of the mutant receptors (Blanpain et al., 1999).
The differences in surface expression between these results
and what was observed in our present study are likely
explained by differences in cell lines and transfection proce-
dures. In CXCR2, Ala substitution of Cys residues hardly
affected surface expression yet the binding of CXCL8 was
completely disrupted, suggesting improper conformation of the
extracellular parts of the receptor (Limatola et al., 2005). As in
CXCR4, a study of CCR6 found that substitution of the 7TM-
conserved bridge retained the receptor in the cell (Ai and Liao,
2002).
Intriguingly, ECL-2 is the largest (although absent in
certain class A receptors such as the metal-ion chelator
receptors (Benned-Jensen et al., 2011) and the most divergent
of all three extracellular loops, yet among chemokine
receptors we here show that the length of ECL-2 is quiteTA
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Fig. 6. Small-molecule ligand activation is retained when disrupting
either of the disulfide bridges in CCR5. IP-accumulation experiments of
Cu2+ bipyridine (CuBip; circles) and Cu2+ phenanthroline (CuPhe;
squares) on CCR5 WT (open symbols) and mutant receptors (closed
symbols). (A) [C178A]-CCR5 represents results from the disrupted 7TM-
conserved bridge. (B) [C269A]-CCR5 represents results from the disrupted
chemokine-conserved bridge. All results are normalized against CCL3-
induced activation of CCR1 WT and are the mean of at least four
experiments.
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conserved (Fig. 1C). Despite the conserved disulfide bridge,
ECL-2 adopts very different structures, ranging from a b-
sheet that dives deep into the ligand-binding pocket (rhodop-
sin) to a more open conformation with an a-helix (b-adrenergic
receptors) as evident from recent crystal structures (Palczewski
et al., 2000; Rasmussen et al., 2007; Hanson et al., 2008;
Jaakola et al., 2008; Scheerer et al., 2008; Warne et al., 2008;
Wu et al., 2010; Peeters et al., 2011). These features are be-
lieved to confer important roles for ligand selectivity among
receptors (Peeters et al., 2011). Furthermore, ECL-2 has been
speculated to adopt different conformations during ligand
binding and receptor activation, first to allow the ligand to
enter the binding crevice and second to stabilize the ligand-
induced receptor conformations (Avlani et al., 2007; Peeters
et al., 2011).
A Disulfide Bridge between the N Terminus and TM-7
Is Conserved in Chemokine Receptors. Additional ex-
tracellular disulfide bridges can be found in subgroups of class
A receptors either within a certain loop (adenosine A2A
receptors) or between the loops and/or the N terminus (e.g.,
chemokine receptors, gonadotropin-releasing hormone receptor,
bradykinin receptor, and GPR39), and are believed to rigidify
the extracellular domains further, thereby providing impor-
tant mechanisms of regulating receptor activity and ligand
binding (Jaakola et al., 2008; Peeters et al., 2011). An
additional disulfide bridge between the N terminus and the
top of TM-7 (and not ECL-3 as previously anticipated) is thus
believed to be present in the majority of endogenous chemo-
kine receptors, as confirmed by the recent structures of
CXCR4 and CXCR1 (Wu et al., 2010; Park et al., 2012). In fact,
only CXCR6 lacks the possibility to form such a disulfide
bridge. Our study clearly supports its presence in CCR1 and
CCR5 (Figs. 2 and 5), as also suggested by previous studies in
CCR5, CXCR1, CXCR2, and CXCR4 (Leong et al., 1994;
Blanpain et al., 1999; Chabot et al., 1999; Limatola et al.,
2005). Yet this may not hold true in all chemokine receptors,
as a study in CCR6 has suggested that this bridge is absent
here (Ai and Liao, 2002).
Previous studies in CCR5 have demonstrated that the N
terminus and ECL-2 are important areas for chemokine as
well as gp120 binding (Lee et al., 1999) and that even minor
alterations in these areas destroy ligand recognition (Samson
Fig. 7. Summary of the dependencies of CCL3 and metal-ion chelators (MC) for extracellular disulfide bridges in CCR1 (A) and CCR5 (B). CCR1 and
CCR5WT are shown in the upper panel. Receptors with a disrupted 7TM-conserved bridge are shown in the middle panel and receptors with a disrupted
chemokine-conserved bridge in the lower panel. (A) Left column: in the presence of CCL3, CCR1 WT is activated (green color), whereas the mutant
receptors binds CCL3 but remains inactive (gray color). The chemokine is suggested to bind in an altered manner when the 7TM-conserved bridge is
disrupted. Middle column: MCs activate both CCR1 WT and mutant receptors with a disrupted chemokine-conserved bridge. Right column: upon
coadministration of MC and CCL3, MC binding increases the affinity of CCL3 in both WT and upon disruption of the chemokine-conserved bridge. In
constructs with a disrupted 7TM-conserved bridge, CCL3 is suggested to bind at a site that overlaps with the MCs so that the two ligands compete. (B)
Left column: in the presence of CCL3, CCR5 WT is activated (green color), whereas CCL3 does not bind to the mutant receptors. Middle column:
contrarily, MCs activate both CCR5 WT and mutant receptors. Right column: as previously described, MCs work as positive allosteric modulators on
CCL3 binding to CCR5 (Thiele et al., 2012). However, as CCL3 binding was absent in the mutant receptors, heterologous binding experiments were not
possible to perform.
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et al., 1997; Dragic et al., 1998). Furthermore, consistent with
our findings in CCR5, Blanpain et al. (1999) have shown that
extracellular conformation-dependent antibodies failed to
recognize CCR5 when one or the other disulfide bridge was
destroyed. Taken together with the overall extracellular bind-
ing mode of chemokines (Pease et al., 1998; Xanthou et al.,
2003), this explains why CCL3 and CCL5 were not able to bind
to CCR5. However, the maintained small molecule activation
in CCR5 (Fig. 6; Supplemental Fig. 2) confirms proper folding
of the transmembrane and intracellular regions in the absence
of the disulfide bridges (Fig. 6).
Chemokines and Small-Molecule Ligands Interact
Differently with Chemokine Receptors. According to the
so-called two-step model initially proposed for the C5a
receptor (Siciliano et al., 1994) and later suggested for the
chemokine system by Pease et al. (1998) and Xanthou et al.
(2003), the chemokine initially interacts with the receptor N
terminus, followed by an interaction with the extracellular
loops. As a last step, the chemokine N terminus initiates
receptor activation, either by docking into the main binding
crevice or via interaction with the extracellular parts
(Schwarz and Wells, 2002). This model was based on
investigations of chemokine interactions with chimeric recep-
tors of CXCR1:3 (Xanthou et al., 2003) and CCR1:3 (Pease
et al., 1998). Also supporting this, CX3CL1 depends on
residues in the N terminus as well as ECL-3 of CX3C
chemokine receptor 1 (Chen et al., 2006), and CXCL16 depends
on all extracellular regions of CXCR6 (Petit et al., 2008).
Likewise, we and others have reported that the chemokine-
induced activation is critically dependent upon the receptor N
terminus in CCR1, CCR2, and CCR8 (Samson et al., 1997;
Jensen et al., 2008, 2012).
Due to the large size of the chemokines, small-molecule
ligands are usually allosteric, with binding sites primary
located in the main binding crevice of the receptors (Berkhout
et al., 2003; de Mendonca et al., 2005; Maeda et al., 2006;
Vaidehi et al., 2006; Rosenkilde et al., 2007; Jensen et al.,
2007, 2008; Thiele et al., 2011). A common pharmacophore of
most small molecules is an elongated structure with a more or
less centered, positively charged group flanked by aromatic
side chains. Several studies have indicated that the positively
charged group anchors to the chemokine receptor-conserved
GluVII:06 and that the aromatic groups interact with the
aromatic environment in the two parts of the main binding
crevice (Rosenkilde and Schwartz, 2006; Rosenkilde et al.,
2010). Yet in many studies the participation of the extracel-
lular domains has been rather neglected. However, as shown
in the crystal structure of CXCR4 (and of the adenosine 2A,
rhodopsin, the b1- and the b2-adrenergic receptors) residues
in ECL-2 may participate directly in the binding of ligands
targeted to the main binding crevices (Palczewski et al., 2000;
Cherezov et al., 2007; Jaakola et al., 2008; Warne et al., 2008;
Wu et al., 2010). Likewise, mutational studies have revealed
participation of ECL-2 in small-molecule ligand binding in
CCR1, CCR5, and CCR8 (Maeda et al., 2006; Thiele et al.,
2011; Jensen et al., 2012).
Disruption of conserved disulfide bridges is likely to
interfere with the active receptor conformations that are
induced by/recognized and stabilized by agonists. Thus,
disulfide bridge-disruption could shift the equilibrium of
active/inactive receptor populations in either direction or open
up for possible ligand interaction to otherwise nonaccessible
conformations. These considerations could explain the alter-
ations in efficacy and Bmax values of both small-molecule and
chemokine agonists. Thus, a shift in receptor population toward
inactive conformations upon disruption of the chemokine-
conserved disulfide bridge could result in proper receptor/
ligand interaction (retained affinity and surface expression but
severely reducedBmax values) though at a concentration too low
to observe activation.
Concerning the 7TM-conserved disulfide bridge, we find
that proper constrainment of ECL-2 is important for the
action but not the binding of chemokine and small-molecule
agonists in CCR1 (Figs. 2, 4, and 5). The shift from ago-
allosteric action on CCR1 WT to competitive displacement of
125I-CCL3 upon disruption of this disulfide bridge (Fig. 5)
indicates an altered binding mode, which along with the
introduced sensitivity of CCL3 for GluVII:06 suggests a com-
petition centered on this residue. In contrast to the findings in
CCR1, the 7TM-conserved bridge was not essential for CCR5
activity, as the small molecules were still able to act in the
absence of C101 or C169, whereas no binding (or action) was
observed for chemokines.
Despite fully conserved positioning of the two disulfide
bridges in CCR1 and CCR5, and a generally conserved
positioning of these among all chemokine receptors (Fig. 1),
the bridges have a very different impact on ligand-mediated
receptor activation. As these observations include two highly
homologous receptors that even share ligand-binding profiles,
it is very likely that disulfide bridges serve different purposes
in not only other chemokine receptors, but in class A receptors
in general.
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Supplemental Figure 2. Small molecule interaction in CCR1 and -5 mutant receptors. The structure of TUG-584 
(CCR1-agonist), Berlex (CCR1-antagonist) and TUG-588 (CCR5-agonist) is shown to the right. IP3-accumulation 
of TUG-584 is shown for CCR1 wt (□), [C106A]-CCR1 (▲), [C183A]-CCR1 (■) (A) and on CCR1 WT (□), [C24A]-
CCR1 (▼), [C273A]-CCR1 (●) (B). Heterologous binding of BX471 on CCR1 WT (□), [C106A]-CCR1 (▲), 
[C183A]-CCR1 (■) (C) and on CCR1 WT (○), [C24A]-CCR1 (▼), [C273A]-CCR1 (●) (D). IP3-accumulation of 
TUG-588 is shown for CCR5 wt (□), [C101A]-CCR5 (▲), [C178A]-CCR5 (■) (E) and on CCR5 WT (□), [C20A]-
CCR5 (▼), [C269A]-CCR5 (●) (F). Receptor activation data is normalized against the WT receptor (CCR1WT  A 
and B, and CCR5 WT  E and F), whereas binding curves are normalized against own values (n=3).
